NCT06374238 Peer Support for Adolescents and Emerging Adults With Sickle Cell Pain
| NCT ID | NCT06374238 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Pittsburgh |
| Condition | Pain |
| Study Type | INTERVENTIONAL |
| Enrollment | 470 participants |
| Start Date | 2025-03-10 |
| Primary Completion | 2027-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 470 participants in total. It began in 2025-03-10 with a primary completion date of 2027-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study, known as the Peer suppoRt for adolescents and Emerging adults with Sickle cell pain: promoting ENgagement in Cognitive behavioral thErapy (PRESENCE), aims to determine the effectiveness of digital CBT in reducing pain, opioid use, and healthcare utilization among AYAs with SCD. It also seeks to understand the role of personalized peer support in enhancing engagement and outcomes of digital CBT interventions. By leveraging existing infrastructure for delivering virtual peer support interventions, tailored digital CBT programs for individuals with SCD, and partnerships with CBOs, the study aims to provide valuable insights into the feasibility and effectiveness of digital CBT as a pain management strategy for this vulnerable population.
Eligibility Criteria
Inclusion Criteria: 1. Aged 16 to 30 years of age at time of enrollment 2. Sickle Cell Disease diagnosis of any genotype based on referral or documentation 3. Reports chronic pain (≥4 days/week for past 3 months or more) OR A) Being prescribed pain medication to be taken (≥4 days/week for past 3 months or more) OR B) Taking pain medication (≥4 days/week for past 3 months or more) OR C) Receiving non-pharmaceutical pain treatment (≥4 days/week for past 3 months or more) 4. Access to an iOS or Android mobile device with internet access Exclusion Criteria: 1. Unable to speak or read English 2. Prior hematopoietic stem cell transplant for sickle cell disease
Contact & Investigator
Charles Jonassaint, PhD
PRINCIPAL INVESTIGATOR
University of Pittsburgh
Frequently Asked Questions
Who can join the NCT06374238 clinical trial?
This trial is open to participants of all sexes, aged 16 Years or older, up to 30 Years, studying Pain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06374238 currently recruiting?
Yes, NCT06374238 is actively recruiting participants. Contact the research team at presencestudy@pitt.edu for enrollment information.
Where is the NCT06374238 trial being conducted?
This trial is being conducted at Mobile, United States, Los Angeles, United States, Hartford, United States, Atlanta, United States and 10 additional locations.
Who is sponsoring the NCT06374238 clinical trial?
NCT06374238 is sponsored by University of Pittsburgh. The principal investigator is Charles Jonassaint, PhD at University of Pittsburgh. The trial plans to enroll 470 participants.